Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.
The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
Patients taking the analgesic tramadol have an increased propensity for hypoglycemia compared to other opioids, according to a new analysis of the Food and Drug Administration’s Adverse Event Reporting Systems.
For many Muslims, fasting is an important part of individual and community life. Healthcare professionals should adopt a patient-centered approach to diabetes care during Ramadan.
A predictive model is presented for hypoglycemia that combines nearly all known and readily assessed risk factors for hypoglycemia such as infection, non-long-acting insulin, and dementia.
Intensive glucose-lowering therapy is prevalent among U.S. adults with diabetes and results in hospitalizations and emergency department visits for hypoglycemia.
Diabetes self-management education and support can cut hypoglycemia risk.
The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older.
FDA has granted Breakthrough Therapy designation to avexitide (Eiger Biopharmaceuticals) for the treatment of post-bariatric hypoglycemia (PBH).
If approved, it would be the first room temperature stable liquid glucagon in an autoinjector formulation.
